The Role of Atypical Infections and Macrolide Therapy in Patients with Asthma

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 5, 2014, Pages 511-517

  Rollins, Donald R ^a   Good, James T ^a   Martin, Richard J ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Airway evaluation; Allergy; Antibiotics and asthma; Asthma; Asthma phenotype; Cytokine; Macrolides; Mycoplasma; Viral infections

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; FLUTICASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KETOLIDE; MACROLIDE; TELITHROMYCIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BACTERIAL INFECTION; BRONCHIOLITIS; BRONCHITIS; CELLULAR IMMUNITY; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DIFFUSE PANBRONCHIOLITIS; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; LOW DRUG DOSE; MYCOPLASMA PNEUMONIAE; MYCOPLASMOSIS; MYCOSIS; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT DURATION; UPREGULATION; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES;

EID: 84926152080     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.06.002     Document Type: Article

References (58)

1. Biscardi S., Lorrot M., Marc E., Moulin F., Boutonnat-Faucher B., Heilbronner C., et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004, 38:1341-1346.
2. Bisgaard H., Hermansen M.N., Buchvald F., Loland L., Halkjaer L.B., Bonnelykke K., et al. Childhood asthma after bacterial colonization of the airway in neonates. NEngl J Med 2007, 357:1487-1495.
3. Emre U., Sokolovskaya N., Roblin P.M., Schachter J., Hammerschlag M.R. Detection of anti-chlamydia pneumoniae IgE in children with reactive airway disease. JInfect Dis 1995, 172:265-267.
4. Gil J.C., Cedillo R.L., Mayagoitia B.G., Paz M.D. Isolation of Mycoplasma pneumoniae from asthmatic patients. Ann Allergy 1993, 70:23-25.
5. Kraft M., Cassell G.H., Pak J., Martin R.J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002, 121:1782-1788.
6. Martin R.J., Kraft M., Chu H.W., Berns E.A., Cassell G.H. Alink between chronic asthma and chronic infection. JAllergy Clin Immunol 2001, 107:595-601.
7. Blasi F., Johnston S.L. The role of antibiotics in asthma. Int J Antimicrob Agents 2007, 29:485-493.
8. Jaffe A., Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31:464-473.
9. Titus A. Data Visualization Series and Global Trends in Macrolide Antibiotic Sales. 2012 Jan 27 [accessed 2014 July 17]. Available from . http://www.cddep.org/blog/posts/data_visualization_series_global_trends_macrolide_antibiotic_sales.
10. Ege M.J., Mayer M., Normand A.C., Genuneit J., Cookson W.O., Braun-Fahrlander C., et al. Exposure to environmental microorganisms and childhood asthma. NEngl J Med 2011, 364:701-709.
11. Caudri D., Wijga A., Scholtens S., Kerkhof M., Gerritsen J., Ruskamp J.M., et al. Early daycare is associated with an increase in airway symptoms in early childhood but is no protection against asthma or atopy at 8 years. Am J Respir Crit Care Med 2009, 180:491-498.
12. Chu H.W., Honour J.M., Rawlinson C.A., Harbeck R.J., Martin R.J. Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 2003, 71:1520-1526.
13. Chu H.W., Rino J.G., Wexler R.B., Campbell K., Harbeck R.J., Martin R.J. Mycoplasma pneumoniae infection increases airway collagen deposition in a murine model of allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol 2005, 289:L125-L133.
14. Dulek D.E., Peebles R.S. Viruses and asthma. Biochim Biophys Acta 2011, 1810:1080-1090.
15. Busse W.W., Lemanske R.F., Gern J.E. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010, 376:826-834.
16. Kennedy J.L., Shaker M., McMeen V., Gern J., Carper H., Murphy D., et al. Comparison of viral load in individuals with and without asthma during infections with rhinovirus. Am J Respir Crit Care Med 2014, 189:532-539.
17. Holgate S.T. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev 2011, 242:205-219.
18. Matsumoto M., Oshiumi H., Seya T. Antiviral responses induced by the TLR3 pathway. Rev Med Virol 2011, 21:67-77.
19. Andersen P. Pathogenesis of lower respiratory tract infections due to chlamydia, mycoplasma, legionella and viruses. Thorax 1998, 53:302-307.
20. Waites K.B., Balish M.F., Atkinson T.P. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008, 3:635-648.
21. Metz G., Kraft M. Effects of atypical infections with mycoplasma and chlamydia on asthma. Immunol Allergy Clin North Am 2010, 30:575-585. vii-viii.
22. Blasi F., Tarsia P., Aliberti S. Chlamydophila pneumoniae. Clin Microbiol Infect 2009, 15:29-35.
23. Kudoh S., Uetake T., Hagiwara K., Hirayama M., Hus L.H., Kimura H., et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1987, 25:632-642.
24. Vanaudenaerde B.M., Vos R., Meyts I., De Vleeschauwer S.I., Verleden S.E., Widyastuti-Willems A., et al. Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back. Inflamm Allergy Drug Targets 2008, 7:279-287.
25. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
26. Spahn J.D., Fost D.A., Covar R., Martin R.J., Brown E.E., Szefler S.J., et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001, 87:501-505.
27. Szefler S.J., Rose J.Q., Ellis E.F., Spector S.L., Green A.W., Jusko W.J. The effect of troleandomycin on methylprednisolone elimination. JAllergy Clin Immunol 1980, 66:447-451.
28. Polasek T.M., Miners J.O. Macrolide-theophylline interactions: no role for the inhibition of cytochrome p4501a2. Br J Clin Pharmacol 2008, 66:898-900.
29. Altenburg J., de Graaff C.S., van der Werf T.S., Boersma W.G. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011, 81:67-74.
30. Kondoh K., Hashiba M., Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol Suppl 1996, 525:56-60.
31. Ichimiya T., Yamasaki T., Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. JAntimicrob Chemother 1994, 34:331-341.
32. Nalca Y., Jansch L., Bredenbruch F., Geffers R., Buer J., Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 2006, 50:1680-1688.
33. Tsang K.W., Ng P., Ho P.L., Chan S., Tipoe G., Leung R., et al. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J 2003, 21:401-406.
34. Kawamura-Sato K., Iinuma Y., Hasegawa T., Horii T., Yamashino T., Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000, 44:2869-2872.
35. Culic O., Erakovic V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429:209-229.
36. Xu G., Fujita J., Negayama K., Yuube K., Hojo S., Yamaji Y., et al. Effect of macrolide antibiotics on macrophage functions. Microbiol Immunol 1996, 40:473-479.
37. Mukae H., Kadota J., Kohno S., Kusano S., Morikawa T., Matsukura S., et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995, 152:613-618.
38. Kadota J., Mizunoe S., Kishi K., Tokimatsu I., Nagai H., Nasu M. Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agents 2005, 25:216-220.
39. Williams A.C., Galley H.F., Watt A.M., Webster N.R. Differential effects of three antibiotics on T helper cell cytokine expression. JAntimicrob Chemother 2005, 56:502-506.
40. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997, 278:901-904.
41. McCaig L.F., Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995, 273:214-219.
42. Hirschmann J.V. Antibiotics for common respiratory tract infections in adults. Arch Intern Med 2002, 162:256-264.
43. Graham V.A., Milton A.F., Knowles G.K., Davies R.J. Routine antibiotics in hospital management of acute asthma. Lancet 1982, I:418-420.
44. Shapiro G.G., Eggleston P.A., Pierson W.E., Ray C.G., Bierman C.W. Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus. Pediatrics 1974, 53:867-872.
45. Sutherland E.R., Martin R.J. Asthma and atypical bacterial infection. Chest 2007, 132:1962-1966.
46. Sutherland E.R., King T.S., Icitovic N., Ameredes B.T., Bleecker E., Boushey H.A., et al. Atrial of clarithromycin for the treatment of suboptimally controlled asthma. JAllergy Clin Immunol 2010, 126:747-753.
47. Brusselle G.G., Joos G. Is there a role for macrolides in severe asthma?. Curr Opin Pulm Med 2014, 20:95-102.
48. Johnston S.L., Blasi F., Black P.N., Martin R.J., Farrell D.J., Nieman R.B. The effect of telithromycin in acute exacerbations of asthma. NEngl J Med 2006, 354:1589-1600.
49. Huang Y.J., Nelson C.E., Brodie E.L., Desantis T.Z., Baek M.S., Liu J., et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. JAllergy Clin Immunol 2011, 127:372-381.e1-3.
50. Hilty M., Burke C., Pedro H., Cardenas P., Bush A., Bossley C., et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
51. Good J.T., Kolakowski C.A., Groshong S.D., Murphy J.R., Martin R.J. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest 2012, 141:599-606.
52. Brusselle G.G., Vanderstichele C., Jordens P., Deman R., Slabbynck H., Ringoet V., et al. Azithromycin for prevention of exacerbations in severe asthma (azisast): amulticentre randomised double-blind placebo-controlled trial. Thorax 2013, 68:322-329.
53. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. NEngl J Med 2012, 366:1881-1890.
54. Svanstrom H., Pasternak B., Hviid A. Use of azithromycin and death from cardiovascular causes. NEngl J Med 2013, 368:1704-1712.
55. Albert R.K., Schuller J.L. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014, 189:1173-1180.
56. Good J.T., Rollins D.R., Martin R.J. Macrolides in the treatment of asthma. Curr Opin Pulm Med 2012, 18:76-84.
57. Rollins D.R., Beuther D.A., Martin R.J. Update on infection and antibiotics in asthma. Curr Allergy Asthma Rep 2010, 10:67-73.
58. Altenburg J., de Graaff C.S., Stienstra Y., Sloos J.H., van Haren E.H., Koppers R.J., et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.